Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Portugal: These 48 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Portugal: These 48 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Portugal?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Portugal Patent 2,101,740

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Portugal?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Portugal Patent 2,086,940

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Portugal?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Portugal Patent 2,101,777

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Portugal?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Portugal Patent 2,091,940

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Portugal?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Portugal Patent 3,176,159

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Portugal?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Portugal Patent 1,988,877

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Portugal?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Portugal Patent 2,120,963

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Portugal?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Portugal Patent 1,973,545

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Portugal?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Portugal Patent 2,495,016

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Portugal?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Portugal Patent 2,079,445

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Portugal?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Portugal Patent 2,079,445

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Portugal?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Portugal Patent 2,137,143

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Portugal?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Portugal Patent 2,380,874

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Portugal?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: Portugal Patent 2,004,646

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can INLYTA (axitinib) generic drug versions launch in Portugal?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Portugal Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Portugal?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Portugal Patent 2,007,756

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Portugal?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Portugal Patent 2,674,428

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Portugal?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Portugal Patent 3,091,011

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Portugal?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Portugal Patent 2,135,199

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Portugal?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Portugal Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Portugal?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Portugal Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Portugal?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Portugal Patent 4,218,732

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Portugal?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Portugal Patent 2,155,696

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Portugal?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Portugal Patent 2,164,473

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Portugal?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Portugal Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Portugal?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Portugal Patent 2,500,014

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Portugal?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Portugal Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Portugal?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Portugal Patent 2,500,014

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Portugal?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Portugal Patent 2,173,752

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Portugal?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Portugal Patent 3,070,090

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Portugal?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Portugal Patent 2,407,475

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Portugal?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Portugal Patent 2,170,050

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can JESDUVROQ (daprodustat) generic drug versions launch in Portugal?

Generic name: daprodustat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 22, 2027
Generic Entry Controlled by: Portugal Patent 2,037,922

JESDUVROQ is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

See drug price trends for JESDUVROQ.

The generic ingredient in JESDUVROQ is daprodustat. Additional details are available on the daprodustat profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Portugal?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Portugal Patent 2,081,921

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Portugal?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Portugal Patent 2,046,318

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Portugal?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Portugal Patent 2,046,318

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Portugal?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Portugal Patent 2,164,844

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Portugal?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Portugal Patent 2,754,660

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Portugal?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Portugal Patent 2,016,940

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Portugal?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Portugal Patent 2,016,940

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Portugal?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Portugal Patent 2,173,891

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Portugal?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Portugal Patent 2,503,004

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Portugal?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Portugal Patent 2,185,157

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Portugal?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Portugal Patent 2,187,965

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Portugal?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Portugal Patent 2,056,832

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Portugal?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Portugal Patent 2,182,988

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Portugal?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Portugal Patent 2,207,526

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Portugal?

Generic name: mirabegron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Portugal Patent 2,216,021

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Portugal?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Portugal Patent 2,097,111

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Portugal?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Portugal Patent 3,699,162

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Portugal?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Portugal Patent 2,097,111

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Portugal?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Portugal Patent 3,699,162

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in Portugal?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 12, 2027
Generic Entry Controlled by: Portugal Patent 2,064,228

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Portugal?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Portugal Patent 2,222,285

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Portugal?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Portugal Patent 3,143,992

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Portugal?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Portugal Patent 3,492,069

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Portugal?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Portugal Patent 3,895,699

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Portugal?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Portugal Patent 2,091,918

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Portugal?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Portugal Patent 2,217,610

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Portugal?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Portugal Patent 2,217,577

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Portugal?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Portugal Patent 2,217,577

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Portugal?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Portugal Patent 2,225,230

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Portugal?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Portugal Patent 3,170,818

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Portugal?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Portugal Patent 2,234,617

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can ONPATTRO (patisiran sodium) generic drug versions launch in Portugal?

Generic name: patisiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2027
Generic Entry Controlled by: Portugal Patent 2,279,254

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

Portugal Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risk and Market Access

Last updated: October 12, 2026

Portugal is an EU pharmaceutical market regulated by INFARMED and the European Medicines Agency framework. The market favors low-cost medicines through reference pricing, mandatory generic substitution, hospital tenders, reimbursement controls and periodic price revisions. Opportunities are strongest in generics, biosimilars, specialty medicines, contract manufacturing, pharmaceutical technology and products addressing shortages. The main barriers are low net prices, delayed reimbursement, public-sector payment pressure, procurement concentration, supply obligations and complex patent and regulatory enforcement.

What is the structure of Portugal’s branded and generic drug market?

Portugal has two principal medicine channels:

Segment Main purchasers Commercial characteristics
Retail prescription medicines SNS patients, pharmacies, private insurers and out-of-pocket buyers Reimbursement tiers, reference pricing and pharmacy substitution
Hospital medicines Public hospitals, hospital centers and specialized institutes Centralized or regional tenders, formulary restrictions and negotiated prices
Non-prescription medicines Consumers and pharmacies Retail competition, advertising restrictions and pharmacy distribution
High-cost specialty medicines Hospitals and public programs Budget controls, managed access and clinical protocol requirements

INFARMED, the National Authority of Medicines and Health Products, authorizes medicines, controls prices, evaluates reimbursement, supervises pharmacovigilance and monitors shortages. The Directorate-General for Health, the SNS and hospital procurement bodies influence treatment protocols and utilization.

Portugal uses EU centralized, decentralized, mutual-recognition and national authorization routes. Innovative products in mandatory centralized categories, including many oncology, orphan, advanced therapy and biotechnology products, receive marketing authorization from the European Commission following an EMA assessment. Generic and hybrid medicines can often use national, decentralized or mutual-recognition procedures under Directive 2001/83/EC and Regulation (EC) No. 726/2004.

How large is the Portuguese pharmaceutical market?

Portugal is a medium-sized EU pharmaceutical market with a population of approximately 10.3 million. Public medicine spending is dominated by the SNS, while private retail and hospital purchasing provide secondary channels. Market value is influenced by medicine prices, reimbursement decisions and the increasing use of high-cost biologics.

The market has four commercial characteristics:

  1. Branded innovative medicines retain value in patented specialties, hospital products and differentiated formulations.
  2. Generics have a structurally strong position after patent expiry.
  3. Biosimilar uptake is expanding but varies by molecule, hospital and clinical area.
  4. Low prices limit the profitability of undifferentiated products.

Portugal’s generic market should be assessed by molecule, dosage form, reimbursement group and channel rather than by a single national share. INFARMED publishes medicine consumption, pricing, reimbursement and market-monitoring information, but market-share figures can differ depending on whether the metric is units, defined daily doses, packs or value.[1]

Which companies compete in Portugal?

The competitive landscape includes multinational originators, European generic groups and Portuguese manufacturers. Relevant Portuguese or Portugal-based participants include:

  • Bial, focused on branded innovative medicines, neurology and epilepsy products.
  • Hovione, a contract development and manufacturing organization with strong capabilities in active pharmaceutical ingredients, inhalation products and drug-device systems.
  • Bluepharma, active in generics, branded generics, contract development and manufacturing.
  • Tecnimede Group, active in generic and branded medicines.
  • Generis, a major Portuguese generic and pharmaceutical products company.
  • Portuguese affiliates of multinational originators and generic companies.

Market access often depends on local regulatory operations, a reliable wholesaler network, pharmacy coverage and the ability to participate in hospital procurement. A foreign company without local infrastructure may need a Portuguese commercial partner, marketing authorization holder, distributor or contract manufacturing arrangement.

How are branded medicines regulated and reimbursed in Portugal?

A marketing authorization does not automatically produce reimbursement or broad commercial access. A company normally must manage separate decisions involving:

  1. Marketing authorization.
  2. Price approval.
  3. Reimbursement classification.
  4. Inclusion in SNS or hospital purchasing channels.
  5. Distribution and supply compliance.

Retail reimbursement is generally based on reference-pricing groups. The reimbursed amount is linked to the reference price for a group of interchangeable medicines, while patient co-payment depends on the reimbursement category and applicable rules. Products with a price above the reference level can create additional patient cost unless the company reduces the price or obtains a different reimbursement position.

For hospital medicines, reimbursement and access can depend on hospital authorization, national treatment programs, tender awards and local formulary decisions. High-cost medicines may require economic evidence, budget-impact analysis and negotiated arrangements.

What opportunities exist for branded pharmaceutical companies?

Commercial opportunities are concentrated in:

  • Oncology and hematology.
  • Rare diseases and orphan medicines.
  • Neurology and immunology.
  • Long-acting injectables.
  • Hospital anti-infectives.
  • Advanced therapies and biotechnology.
  • Pediatric and geriatric formulations.
  • Drug-device combinations.
  • Medicines addressing persistent shortages.

A product with limited clinical differentiation may face a difficult Portuguese launch because pricing and reimbursement pressure can outweigh the value of a standalone marketing authorization. Products with strong clinical outcomes, reduced hospital use or a clear unmet need have better prospects in reimbursement negotiations.

What are the main opportunities for generic drug companies?

Portugal provides a favorable legal environment for generics after loss of patent or SPC protection. Generic companies can rely on the reference product’s regulatory dossier after the applicable data and market exclusivity periods expire. The EU "Bolar" exemption permits certain studies and trials needed for generic authorization before patent expiry, subject to national implementation and legal limits.[2]

Generic substitution is a core market-access mechanism. Pharmacists generally must inform patients about available less expensive alternatives and may substitute in accordance with applicable prescription and reimbursement rules, subject to physician and patient exceptions.

The strongest generic opportunities are usually:

Opportunity Why it is attractive
First generic entry Temporary share advantage before additional competitors
Complex generics Higher development and regulatory barriers
Hospital injectables Shortage exposure and procurement demand
Inhalation products Device and formulation barriers reduce competition
Modified-release products Bioequivalence and formulation complexity
Generic biologics and biosimilars Large originator spending pools
Products with few suppliers Greater pricing resilience
Local manufacturing or packaging Supports supply reliability and procurement credibility

The commercial risk is rapid price erosion. Once multiple suppliers enter, Portugal’s reference-pricing and tender systems can compress margins. A generic launch plan therefore requires supply reliability, competitive pricing, portfolio breadth and careful forecasting of wholesaler and pharmacy inventory.

What patent and exclusivity rules apply in Portugal?

Portugal follows the European patent and pharmaceutical exclusivity framework. Patent rights may arise from:

  • European patents validated in Portugal.
  • Unitary patents covering Portugal.
  • National Portuguese patents.
  • Supplementary protection certificates.
  • Patent applications covering formulation, dosage, manufacturing or therapeutic use.

A standard pharmaceutical patent generally expires 20 years from the filing date, subject to adjustments and applicable rules. An SPC can extend protection for an authorized active ingredient by up to five years, with a possible additional six-month pediatric extension under Regulation (EC) No. 469/2009 and the pediatric framework.[3]

There is no single national expiry calendar for Portugal. The relevant date must be calculated from the specific patent family, validation status, SPC, pediatric extension, regulatory exclusivity and any litigation or settlement restrictions.

What patents protect branded medicines in Portugal?

The most important patent categories are:

Patent category Commercial purpose
Compound patent Protects the active pharmaceutical ingredient
Salt, polymorph or crystal patent Protects a particular chemical form
Formulation patent Protects release profile, excipients or dosage form
Device patent Protects inhalers, injectors, pens or delivery systems
Method-of-use patent Protects treatment of a disease or patient subgroup
Manufacturing patent Protects synthesis, purification or process control
Combination patent Protects use of two or more active ingredients

Formulation and method-of-use patents can remain commercially relevant after compound-patent expiry. Their enforceability depends on claim construction, product labeling, national implementation of second-medical-use rules and the facts of the alleged infringement.

When does a branded drug lose exclusivity in Portugal?

Exclusivity can end in stages:

Protection Typical timing or effect
Regulatory data exclusivity Generally eight years in the EU
Regulatory market exclusivity Generally two additional years
Pediatric extension Potential additional six months
Basic patent Generally 20 years from filing
SPC Up to five additional years after patent expiry
Orphan-market exclusivity Generally 10 years, subject to exceptions and possible extension
Supplementary patent claims May delay practical generic entry even after compound expiry

The "8+2+1" system can permit an additional year of market protection for a significant new therapeutic indication. Regulatory and patent exclusivity are separate. A generic may receive authorization before patent expiry but remain unable to launch until enforceable patent rights expire or are successfully challenged.

What is the Orange Book status of Portugal?

Portugal does not have a U.S.-style Orange Book. There is no single Portuguese publication that performs the same function as the FDA Orange Book for approved products and listed patents.

Companies should instead review:

  • INFARMED marketing-authorization databases.
  • The European Commission’s Union Register.
  • EMA product information and EPARs.
  • The European Patent Register.
  • The Portuguese Industrial Property Institute, INPI.
  • European patent validation and legal-status records.
  • SPC registers.
  • Portuguese court and EU case-law databases.

For an entry analysis, the relevant question is not whether a product appears in an Orange Book. It is whether an enforceable Portuguese patent, unitary patent, SPC, regulatory restriction or settlement agreement prevents launch.

How do Paragraph IV challenges work in Portugal?

Portugal does not use the U.S. Hatch-Waxman Paragraph IV system. A Portuguese generic applicant does not file a U.S.-style Paragraph IV certification against listed patents.

Patent challenges can instead arise through:

  • Opposition at the European Patent Office.
  • National invalidity proceedings.
  • Non-infringement actions.
  • Declaratory proceedings.
  • Patent revocation or limitation.
  • Preliminary injunction proceedings.
  • Patent litigation after a launch or threatened launch.
  • UPC proceedings for eligible European patents and unitary patents.

A generic company can seek market-entry certainty through an early freedom-to-operate assessment, patent validity review and, where appropriate, litigation or negotiated settlement. The absence of Paragraph IV does not remove patent risk. It changes the procedural route and timing.

What patent litigation affects Portuguese generic entry?

Litigation risk is highest when a product has:

  • A recent SPC.
  • Multiple formulation or device patents.
  • A second-medical-use patent.
  • A complex manufacturing process.
  • A narrow therapeutic indication.
  • A history of enforcement in other European jurisdictions.
  • A potential preliminary injunction.

Portugal is part of the EU patent litigation environment. The Unified Patent Court can affect unitary patents and eligible European patents, while Portuguese courts remain relevant for national rights and matters outside UPC jurisdiction. A single UPC action can create broader European exposure than a national Portuguese proceeding.

What is the biosimilar opportunity in Portugal?

Portugal is an expanding biosimilar market, particularly in hospital-administered biologics. Opportunities include oncology, immunology, diabetes, ophthalmology and supportive care.

Biosimilar authorization follows the EU’s centralized scientific framework. EMA and national stakeholders assess comparability, quality, analytical similarity, nonclinical data and clinical evidence under product-specific guidelines.[4] Authorization does not guarantee automatic substitution. Interchangeability and substitution policies remain subject to national and institutional rules.

What are the main biosimilar barriers?

The main barriers are:

  • Hospital physician adoption.
  • Tender concentration and price competition.
  • Brand loyalty for complex biologics.
  • Limited interchangeability rules.
  • Manufacturing scale and cold-chain requirements.
  • Immunogenicity and pharmacovigilance obligations.
  • Originator litigation involving formulation, device or dosing patents.

Biosimilar entrants with multiple molecules, dependable supply and local medical affairs capacity are better positioned than companies pursuing isolated products.

What FDA regulatory status applies to Portuguese medicines?

FDA approval is not required for a medicine marketed only in Portugal. Portuguese products use EU and national authorization pathways, not the U.S. FDA system.

FDA approval may still matter where:

  • The product is intended for U.S. commercialization.
  • The company relies on U.S. clinical or manufacturing data.
  • A global regulatory strategy uses a common dossier.
  • Investors assess international commercial value.
  • A U.S. reference product is relevant to development.

For Portugal, the controlling regulatory institutions are INFARMED, EMA and the European Commission.

What licensing deals and manufacturing opportunities exist?

Portugal is relevant to pharmaceutical licensing because it has:

  • Local companies with EU regulatory experience.
  • Contract development and manufacturing capacity.
  • API and inhalation expertise.
  • Established EU distribution infrastructure.
  • A base for broader European commercialization.

Bial’s international partnerships, including licensing arrangements for epilepsy products, illustrate how Portuguese-origin innovation can be commercialized through multinational partners.[5] Hovione’s business model demonstrates the value of Portuguese manufacturing and development capabilities in APIs, inhalation and drug-product technology.[6]

Typical transaction structures include:

  • In-licensing of generics for Portugal and selected EU markets.
  • Out-licensing of Portuguese-origin innovative medicines.
  • Co-development of complex generics.
  • Contract manufacturing and technology transfer.
  • Distribution agreements with local commercial partners.
  • Portfolio acquisitions involving national marketing authorizations.
  • Regional licensing for hospital products and biosimilars.

Due diligence should cover patent ownership, regulatory responsibility, pharmacovigilance, serialization, supply commitments, reimbursement history, tender exposure, transfer pricing and termination rights.

What supply-chain and manufacturing barriers affect market entry?

Portugal imposes EU good manufacturing practice, pharmacovigilance, serialization and wholesale distribution requirements. Manufacturers and marketing-authorization holders must maintain compliant quality systems and notify relevant authorities of supply disruptions.

Shortages are a significant operational risk. A company can hold regulatory approval but lose commercial access if it cannot maintain supply. Hospital tenders may impose delivery penalties, minimum stock obligations and strict technical specifications.

Manufacturing-related IP can also delay entry. A generic may avoid a compound patent but still face:

  • Process patents.
  • Crystalline-form patents.
  • Device patents.
  • Combination-product rights.
  • Trade-secret risks in technology transfer.
  • Regulatory dependence on a contract manufacturer.

Portugal is commercially attractive for localized packaging, release testing, API supply and specialized manufacturing, but labor, energy, quality and scale economics must be assessed against lower-cost EU and non-EU alternatives.

What generic launch scenarios exist in Portugal?

Launch scenario Main condition Expected risk
Day-one launch at patent expiry No enforceable patent or SPC remains High price competition
At-risk launch Validity or infringement position is favorable Injunction and damages exposure
Delayed launch Formulation or use patent remains Lower litigation risk, lost first-mover share
Settlement launch Entry date negotiated with originator Contract and competition-law review
Hospital-first launch Tender access precedes retail rollout Procurement concentration
Shortage-response launch Supply gap creates demand Regulatory and operational urgency

A launch decision should combine patent status, SPC analysis, regulatory exclusivity, reimbursement timing, supply capacity and competitor readiness. The earliest legally possible launch is not always the best commercial launch.

How strong is the Portuguese patent estate compared with other EU markets?

Portugal’s patent rights are integrated into the broader European system. A product may have the same European patent family, SPC strategy and litigation posture across multiple EU countries. Portugal is therefore rarely assessed in isolation.

Compared with larger EU markets, Portugal has:

  • Lower absolute sales potential.
  • Strong exposure to public purchasing.
  • High sensitivity to reimbursement price.
  • Less tolerance for supply interruption.
  • Importance as part of a multi-country launch sequence.
  • Potential UPC relevance for unitary or opted-in European patents.

The Portuguese market can be commercially important for launch sequencing, real-world evidence, hospital adoption and regional supply, even where it does not determine the global return on investment.

What are the principal regulatory opportunities and challenges?

Area Opportunity Challenge
Generics Strong substitution and post-expiry demand Rapid price erosion
Biosimilars Hospital savings and large biologic markets Interchangeability and tender pressure
Innovative drugs Orphan, oncology and specialty access Reimbursement delay and evidence demands
Manufacturing API, inhalation and complex-product expertise Compliance and scale costs
Licensing Local partners and EU market reach Contract, IP and pharmacovigilance allocation
Shortage products Public need and procurement opportunities Supply obligations and low margins
Digital and combination products Growing regulatory demand Classification and evidence complexity

Key Takeaways

  • Portugal is a price-sensitive EU market controlled by INFARMED, the SNS, reimbursement rules and hospital procurement.
  • Generic substitution and reference pricing support post-patent competition but compress margins.
  • Portugal has no U.S.-style Orange Book and no Paragraph IV procedure.
  • Patent analysis must cover European patents, unitary patents, Portuguese rights, SPCs, formulation claims, method-of-use claims and manufacturing patents.
  • Biosimilar growth is strongest in hospital medicines, but substitution and tender rules remain commercially decisive.
  • Portuguese companies provide licensing, manufacturing, API, inhalation and generic-development opportunities.
  • Regulatory approval alone does not ensure reimbursement, hospital access or profitable launch.
  • The highest-value diligence areas are patent expiry, SPC status, reimbursement timing, tender structure, supply obligations and local partner quality.

Frequently Asked Questions

Can a generic medicine launch in Portugal before the reference product’s patent expires?

It can obtain regulatory authorization under the EU Bolar framework, but commercial launch may still infringe an enforceable patent, SPC, formulation claim, device claim or method-of-use claim.

Does Portugal automatically substitute biosimilars at the pharmacy?

No. Biosimilar interchangeability and substitution depend on national policy, product characteristics and institutional or clinical rules. Hospital procurement often has a greater effect than retail pharmacy substitution.

Are Portuguese medicine prices linked to Spain?

Portugal uses international and reference-pricing mechanisms that can consider prices in other countries, including European reference markets. The precise methodology depends on the applicable product category and reimbursement process.

Can a company use a centralized EU marketing authorization to sell in Portugal?

Yes, where the product is covered by the centralized authorization. The company must still manage Portuguese pricing, reimbursement, pharmacovigilance, supply and commercial requirements.

Is a Portuguese patent litigation case enough to block EU-wide generic entry?

Usually no. A Portuguese action primarily affects Portuguese rights and market exposure, although a UPC proceeding or a coordinated European litigation strategy can have broader geographic consequences.

References

  1. INFARMED, I.P. (2024). Medicines market monitoring and pharmaceutical consumption information. Portuguese National Authority of Medicines and Health Products.

  2. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union.

  3. European Parliament and Council. (2009). Regulation (EC) No. 469/2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union.

  4. European Medicines Agency. (2023). Biosimilar medicines: Overview and regulatory information. EMA.

  5. Bial. (2024). International partnerships and product portfolio. Bial, Portela & C.A., S.A.

  6. Hovione. (2024). Contract development and manufacturing capabilities. Hovione FarmaCiencia SA.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.